Our thanks to Corcept Therapeutics for sharing this enlightening panel discussion of the evolution of hypercortisolism moderated by Mike Evans, Senior Director of Commercial Insights at Corcept.
In this brief podcast, Dr. Blevins relates a fascinating Cushings case to talk about the importance of understanding disease patterns and how depth of knowledge gives physicians the critical skills to recognize unusual conditions.
If you have Cushing’s and take Recordati’s new drug Isturisa, there are two websites, Cushing’s Inspirations and Cushing’s Conversations, where you can share your story and connect with others. The sites are designed to engage and connect people
With today’s podcasts from this week’s live-talk show, Dr. Blevins recaps our content dedicated to Global Cushing’s month with a talk about two fascinating recent Cushing cases from his practice. He also touches on some very interesting caveats about thyroid hormone replacement.
Listen to this fascinating discussion of adrenal Cushing’s or hypercortisolism as Dr. Lewis Blevins walks us through the disease’s characteristics, biochemistry, and treatment options. In the talk, he focuses on different conditions, including adrenal adenomas, adrenal cancer, adrenal hyperplasia, and other related diseases like Carney Complex and McCune-Albright syndrome.
A roundtable on hypercortisolism perspectives recently sponsored by Corcept Therapeutics highlights diagnosis and management in community and academic settings. A group of leading clinicians and educators offer their experiences and views in this fascinating article. Key
It’s always fascinating to listen to two of the recognized experts and leading clinicians in Cushing’s disease discuss their experiences with the disease and patients. In this Live Talk session, Pituitary World New’s innovative program for education and awareness, Dr. Kevin Yuen and Dr. Lewis Blevins bring an intimate, revealing look at their approaches to Cushing’s disease and syndrome.
I’m happy to welcome Leslie Edwin, president of Cushing’s Support and Research Foundation (CSRF), to our microphones. The CSRF is a leading Cushing’s disease and syndrome patient support organization.
This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,